Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer

Author(s): Florencia Zalazar, Paola De Luca, Kevin Gardner, William D. Figg, Roberto Meiss, Raúl G. Spallanzani, Pablo Vallecorsa, Belén Elguero, Javier Cotignola, Elba Vazquez, Adriana De Siervi*.

Journal Name: Current Pharmaceutical Biotechnology

Volume 20 , Issue 12 , 2019

Become EABM
Become Reviewer

Abstract:

Due to some inconsistencies in the figures provided by the first author that have come to light, and after a thorough investigation we would like to retract our paper: “Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. By: Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A. Curr. Pharm. Biotechnol., 2015, 16(6), 553-63.

Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. As such this article represents a severe abuse of the scientific publishing system. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 12
Year: 2019
Page: [1072 - 1072]
Pages: 1
DOI: 10.2174/138920102012190919103433

Article Metrics

PDF: 13